Lupin Q3 FY26 consolidated PAT jumped 37.4% to Rs. 1,180.5 Cr
U.S. market achieved record quarterly sales of Rs. 3,113.2 crore ($350 million), a 54% YoY increase, accounting for 44% of global sales
U.S. market achieved record quarterly sales of Rs. 3,113.2 crore ($350 million), a 54% YoY increase, accounting for 44% of global sales
Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ecosystem and strengthen health security
Revenue from operations rose to Rs. 23,637 million for the three months ended December 31, 2025
The milestone means more than 1,000 men are now enrolled across both Phase 3 programs
The paper highlights how conditions common across India—including anemia, inherited hemoglobin disorders, and glucose-6-phosphate dehydrogenase (G6PD) deficiency—can significantly distort HbA1c readings
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
The revenues this quarter are in line with the outlook we envisaged for the year
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
Subscribe To Our Newsletter & Stay Updated